查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1179735

亨廷顿舞蹈病治疗市场：按药物类型、年龄和分销渠道分类：2021-2031 年全球机会分析和行业预测

Huntington's Disease Treatment Market By Drug type, By Age, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 301 Pages | 商品交期: 2-3个工作天内

价格

亨廷顿舞蹈症是一种罕见的遗传病，会导致大脑中的神经细胞进行性破坏。

症状出现的速度因人而异。 在某些人中，首先出现运动能力的变化，然后是抑郁症状。 此外，情绪波动和奇怪的行为是众所周知的早期预警信号。 亨廷顿舞蹈症会导致运动、认知和心理问题，这些问题会极大地影响一个人的工作能力。 药物可用于控制亨廷顿病的症状。 目前还没有批准用于亨廷顿病患者的疾病缓解药物。

推动亨廷顿舞蹈症药物市场增长的主要因素是该病的患病率不断上升，以及对控制与亨廷顿舞蹈症相关症状的先进药物类型的需求不断增加。 此外，强大的药物类型管道是一个关键的市场趋势，预计将在预测期内推动增长。

患者数量的急剧增加是市场的关键因素之一，因为患者数量的增加导致对药物的需求增加。 例如，发表在 BJM 杂誌上的一篇研究论文发现英国的 HD 患病率很高。 如此高的 HD 患病率需要更多的独创性和反应性来治疗。 因此，如此高的病例数有望推动亨廷顿病药物市场的增长。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章亨廷顿病药物市场：按药物类型分类

  • 概览
    • 市场规模和预测
  • 批准的药物
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
    • 亨廷顿舞蹈病治疗市场批准的药物：按类型分类
      • 丁苯那秦市场规模和预测：按地区
      • Doytetrabenazine 市场规模转变和预测：按地区
  • 标籤外药物
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 5 章亨廷顿病药物市场：按年龄分类

  • 概览
    • 市场规模和预测
  • 50 岁以下
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 50 岁以上
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 6 章亨廷顿病药物市场：按分销渠道

  • 概览
    • 市场规模和预测
  • 医院药房
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 药店和零售药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类
  • 在线药店
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场份额分析：按国家/地区分类

第 7 章亨廷顿病药物市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机会
    • 北美市场规模和预测：按药物类型
      • 北美批准的药物亨廷顿氏病治疗市场：按类型分类
    • 北美市场规模和预测：按年龄段
    • 北美市场规模和预测：按分销渠道
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按药物类型
      • 欧洲批准的药物亨廷顿舞蹈病药物市场：按类型分类
    • 欧洲市场规模和预测：按年龄段
    • 欧洲市场规模和预测：按分销渠道
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲地区
  • 亚太地区
    • 主要趋势和机会
    • 亚太地区市场规模和按药物类型预测
      • 亚太地区批准的药物亨廷顿氏病治疗市场，按类型
    • 亚太市场规模和预测：按年龄段
    • 亚太市场规模和预测：按分销渠道
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按药物类型
      • LAMEA 批准的药物亨廷顿氏病治疗市场：按类型分类
    • LAMEA 市场规模和预测：按年龄段
    • LAMEA 市场规模和预测：按分销渠道
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • LAMEA 的其余部分

第八章公司情况

  • 简介
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第九章公司简介

  • Prilenia Therapeutics
  • som biotech
  • Bausch Health Companies Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Lupin
  • UniQure
  • Hikma Pharmaceuticals plc
  • Annexon Biosciences
  • Dr. Reddy's Laboratories Ltd.
  • Neurocrine Biosciences
  • PTC Therapeutics
  • AOP Health
  • Medesis Pharma SA
  • Mitochon Pharmaceuticals
  • Sun Pharmaceuticals Industries Ltd.
  • Vaccinex, Inc
Product Code: A17522

Huntington's disease is a rare, genetic condition that results in progressive destruction of brain nerve cells. The rate at which symptoms appear can differ from person to person. For some people, motor skill changes come first, followed by depressive symptoms. Changes in mood and strange behavior are frequent early warning indicators. Functional capacities of a person are significantly impacted by Huntington's  disease, which typically causes mobility, cognitive, and psychological issues. Medications are available to help manage symptoms of Huntington's disease. There is currently no authorized disease-modifying medication for patients with Huntington's disease.

Major factors that drive growth of the Huntington's disease treatment market is increase in prevalence population and rise in demand for advanced drug types for controlling symptoms associated with Huntington's. In addition, strong drug type pipeline is a key trend in the market, which is expected to fuel growth during the forecast period.

Significant surge in patient population is one of the leading factors in the market as rise in patient lead to increase in demand for drugs. For instance, according to a research paper published by BJM Journal, there is high prevalence of HD in the UK. Such high prevalence of HD requires more ingenuity and responsiveness in its care. Thus, such high number of cases are expected to boost the Huntington's disease treatment market growth.

In addition, surge in demand for advanced treatment such as gene therapy and stem cell therapy in the past decade drives the market growth. Furthermore, rise in R&D investments in drug discovery and development serves as an lucrative opportunity for the market growth. However, complications associated with drug development process expected to hamper the market growth.

The global Huntington's disease treatment market is segmented on the basis of drug type, age, distribution channel, and region. On the basis of drug type, the market is categorized into approved drugs and off-label drugs. The approved drug segment is further classified into tetrabenazine and deutetrabenazine. By age, the market is divided into below 50 years and above 50 years. By distribution channel, it is segmented into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and Latin America, the Middle East, and Africa (LAMEA).

Major players profiled in the report are Annexon Biosciences, Bausch Health Companies Inc, Dr.Reddy's Laboratories Ltd, Eli Lilly And Company, Hikma Pharmaceuticals PLC, Lupin, Medesis pharma SA, Mitochon Pharmaceuticals, Neurocrine bioscience Inc., Novartis, PTC Therapeutics, Inc, SOM Biotech, Sun Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., UniQure, and Vaccinex, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the huntington's disease treatment market analysis from 2021 to 2031 to identify the prevailing huntington's disease treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the huntington's disease treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global huntington's disease treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug type

  • Approved drugs
    • Type
    • Tetrabenazine
    • Deutetrabenazine
  • Offlabel drugs

By Age

  • Below 50 years
  • Above 50 years

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Prilenia Therapeutics
    • som biotech
    • Bausch Health Companies Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Lupin
    • UniQure
    • Hikma Pharmaceuticals plc
    • Annexon Biosciences
    • Dr. Reddy's Laboratories Ltd.
    • Neurocrine Biosciences
    • PTC Therapeutics
    • AOP Health
    • Medesis Pharma SA
    • Mitochon Pharmaceuticals
    • Sun Pharmaceuticals Industries Ltd.
    • Vaccinex, Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Approved drugs
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
    • 4.2.4 Approved drugs Huntington's Disease Treatment Market by Type
      • 4.2.4.1 Tetrabenazine Market size and forecast, by region
      • 4.2.4.2 Deutetrabenazine Market size and forecast, by region
  • 4.3 Offlabel drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country

CHAPTER 5: HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Below 50 years
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 Above 50 years
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Drug store and retail pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug type
      • 7.2.2.1 North America Approved drugs Huntington's Disease Treatment Market by Type
    • 7.2.3 North America Market size and forecast, by Age
    • 7.2.4 North America Market size and forecast, by Distribution channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Drug type
      • 7.2.5.1.3 Market size and forecast, by Age
      • 7.2.5.1.4 Market size and forecast, by Distribution channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Drug type
      • 7.2.5.2.3 Market size and forecast, by Age
      • 7.2.5.2.4 Market size and forecast, by Distribution channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Drug type
      • 7.2.5.3.3 Market size and forecast, by Age
      • 7.2.5.3.4 Market size and forecast, by Distribution channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug type
      • 7.3.2.1 Europe Approved drugs Huntington's Disease Treatment Market by Type
    • 7.3.3 Europe Market size and forecast, by Age
    • 7.3.4 Europe Market size and forecast, by Distribution channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Drug type
      • 7.3.5.1.3 Market size and forecast, by Age
      • 7.3.5.1.4 Market size and forecast, by Distribution channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Drug type
      • 7.3.5.2.3 Market size and forecast, by Age
      • 7.3.5.2.4 Market size and forecast, by Distribution channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Drug type
      • 7.3.5.3.3 Market size and forecast, by Age
      • 7.3.5.3.4 Market size and forecast, by Distribution channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Drug type
      • 7.3.5.4.3 Market size and forecast, by Age
      • 7.3.5.4.4 Market size and forecast, by Distribution channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Drug type
      • 7.3.5.5.3 Market size and forecast, by Age
      • 7.3.5.5.4 Market size and forecast, by Distribution channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Drug type
      • 7.3.5.6.3 Market size and forecast, by Age
      • 7.3.5.6.4 Market size and forecast, by Distribution channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug type
      • 7.4.2.1 Asia-Pacific Approved drugs Huntington's Disease Treatment Market by Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Age
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Drug type
      • 7.4.5.1.3 Market size and forecast, by Age
      • 7.4.5.1.4 Market size and forecast, by Distribution channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Drug type
      • 7.4.5.2.3 Market size and forecast, by Age
      • 7.4.5.2.4 Market size and forecast, by Distribution channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Drug type
      • 7.4.5.3.3 Market size and forecast, by Age
      • 7.4.5.3.4 Market size and forecast, by Distribution channel
      • 7.4.5.4 Australia
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Drug type
      • 7.4.5.4.3 Market size and forecast, by Age
      • 7.4.5.4.4 Market size and forecast, by Distribution channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Drug type
      • 7.4.5.5.3 Market size and forecast, by Age
      • 7.4.5.5.4 Market size and forecast, by Distribution channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Drug type
      • 7.4.5.6.3 Market size and forecast, by Age
      • 7.4.5.6.4 Market size and forecast, by Distribution channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug type
      • 7.5.2.1 LAMEA Approved drugs Huntington's Disease Treatment Market by Type
    • 7.5.3 LAMEA Market size and forecast, by Age
    • 7.5.4 LAMEA Market size and forecast, by Distribution channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Drug type
      • 7.5.5.1.3 Market size and forecast, by Age
      • 7.5.5.1.4 Market size and forecast, by Distribution channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Drug type
      • 7.5.5.2.3 Market size and forecast, by Age
      • 7.5.5.2.4 Market size and forecast, by Distribution channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Drug type
      • 7.5.5.3.3 Market size and forecast, by Age
      • 7.5.5.3.4 Market size and forecast, by Distribution channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Drug type
      • 7.5.5.4.3 Market size and forecast, by Age
      • 7.5.5.4.4 Market size and forecast, by Distribution channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Prilenia Therapeutics
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 som biotech
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Teva Pharmaceutical Industries Ltd.
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Novartis AG
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Lupin
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 UniQure
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Hikma Pharmaceuticals plc
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Annexon Biosciences
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Dr. Reddy's Laboratories Ltd.
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Neurocrine Biosciences
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 PTC Therapeutics
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments
  • 9.13 AOP Health
    • 9.13.1 Company overview
    • 9.13.2 Company snapshot
    • 9.13.3 Operating business segments
    • 9.13.4 Product portfolio
    • 9.13.5 Business performance
    • 9.13.6 Key strategic moves and developments
  • 9.14 Medesis Pharma SA
    • 9.14.1 Company overview
    • 9.14.2 Company snapshot
    • 9.14.3 Operating business segments
    • 9.14.4 Product portfolio
    • 9.14.5 Business performance
    • 9.14.6 Key strategic moves and developments
  • 9.15 Mitochon Pharmaceuticals
    • 9.15.1 Company overview
    • 9.15.2 Company snapshot
    • 9.15.3 Operating business segments
    • 9.15.4 Product portfolio
    • 9.15.5 Business performance
    • 9.15.6 Key strategic moves and developments
  • 9.16 Sun Pharmaceuticals Industries Ltd.
    • 9.16.1 Company overview
    • 9.16.2 Company snapshot
    • 9.16.3 Operating business segments
    • 9.16.4 Product portfolio
    • 9.16.5 Business performance
    • 9.16.6 Key strategic moves and developments
  • 9.17 Vaccinex, Inc
    • 9.17.1 Company overview
    • 9.17.2 Company snapshot
    • 9.17.3 Operating business segments
    • 9.17.4 Product portfolio
    • 9.17.5 Business performance
    • 9.17.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 2. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR APPROVED DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 3. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR APPROVED DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 4. GLOBAL APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 5. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR TETRABENAZINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 6. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR DEUTETRABENAZINE, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 7. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR OFFLABEL DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 8. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR OFFLABEL DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 9. GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR BELOW 50 YEARS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR BELOW 50 YEARS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ABOVE 50 YEARS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ABOVE 50 YEARS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. HUNTINGTON'S DISEASE TREATMENT MARKET, FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. NORTH AMERICA APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. NORTH AMERICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. U.S. HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. U.S. HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. U.S. HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. CANADA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. CANADA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. CANADA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. EUROPE APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. UK HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. UK HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. UK HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. ITALY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. ITALY HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. ITALY HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. ASIA-PACIFIC APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. CHINA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. CHINA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. CHINA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. INDIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. INDIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. INDIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. LAMEA APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY AGE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99.PRILENIA THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 100.PRILENIA THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 101.PRILENIA THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 102.PRILENIA THERAPEUTICS: NET SALES,
  • TABLE 103.PRILENIA THERAPEUTICS: KEY STRATERGIES
  • TABLE 104.SOM BIOTECH: COMPANY SNAPSHOT
  • TABLE 105.SOM BIOTECH: OPERATING SEGMENTS
  • TABLE 106.SOM BIOTECH: PRODUCT PORTFOLIO
  • TABLE 107.SOM BIOTECH: NET SALES,
  • TABLE 108.SOM BIOTECH: KEY STRATERGIES
  • TABLE 109.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 110.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 111.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 112.BAUSCH HEALTH COMPANIES INC.: NET SALES,
  • TABLE 113.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
  • TABLE 114.TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 115.TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 116.TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 117.TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES,
  • TABLE 118.TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 119.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 120.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 121.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 122.NOVARTIS AG: NET SALES,
  • TABLE 123.NOVARTIS AG: KEY STRATERGIES
  • TABLE 124.LUPIN: COMPANY SNAPSHOT
  • TABLE 125.LUPIN: OPERATING SEGMENTS
  • TABLE 126.LUPIN: PRODUCT PORTFOLIO
  • TABLE 127.LUPIN: NET SALES,
  • TABLE 128.LUPIN: KEY STRATERGIES
  • TABLE 129.UNIQURE: COMPANY SNAPSHOT
  • TABLE 130.UNIQURE: OPERATING SEGMENTS
  • TABLE 131.UNIQURE: PRODUCT PORTFOLIO
  • TABLE 132.UNIQURE: NET SALES,
  • TABLE 133.UNIQURE: KEY STRATERGIES
  • TABLE 134.HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
  • TABLE 135.HIKMA PHARMACEUTICALS PLC: OPERATING SEGMENTS
  • TABLE 136.HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
  • TABLE 137.HIKMA PHARMACEUTICALS PLC: NET SALES,
  • TABLE 138.HIKMA PHARMACEUTICALS PLC: KEY STRATERGIES
  • TABLE 139.ANNEXON BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 140.ANNEXON BIOSCIENCES: OPERATING SEGMENTS
  • TABLE 141.ANNEXON BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 142.ANNEXON BIOSCIENCES: NET SALES,
  • TABLE 143.ANNEXON BIOSCIENCES: KEY STRATERGIES
  • TABLE 144.DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT
  • TABLE 145.DR. REDDY'S LABORATORIES LTD.: OPERATING SEGMENTS
  • TABLE 146.DR. REDDY'S LABORATORIES LTD.: PRODUCT PORTFOLIO
  • TABLE 147.DR. REDDY'S LABORATORIES LTD.: NET SALES,
  • TABLE 148.DR. REDDY'S LABORATORIES LTD.: KEY STRATERGIES
  • TABLE 149.NEUROCRINE BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 150.NEUROCRINE BIOSCIENCES: OPERATING SEGMENTS
  • TABLE 151.NEUROCRINE BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 152.NEUROCRINE BIOSCIENCES: NET SALES,
  • TABLE 153.NEUROCRINE BIOSCIENCES: KEY STRATERGIES
  • TABLE 154.PTC THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 155.PTC THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 156.PTC THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 157.PTC THERAPEUTICS: NET SALES,
  • TABLE 158.PTC THERAPEUTICS: KEY STRATERGIES
  • TABLE 159.AOP HEALTH: COMPANY SNAPSHOT
  • TABLE 160.AOP HEALTH: OPERATING SEGMENTS
  • TABLE 161.AOP HEALTH: PRODUCT PORTFOLIO
  • TABLE 162.AOP HEALTH: NET SALES,
  • TABLE 163.AOP HEALTH: KEY STRATERGIES
  • TABLE 164.MEDESIS PHARMA SA: COMPANY SNAPSHOT
  • TABLE 165.MEDESIS PHARMA SA: OPERATING SEGMENTS
  • TABLE 166.MEDESIS PHARMA SA: PRODUCT PORTFOLIO
  • TABLE 167.MEDESIS PHARMA SA: NET SALES,
  • TABLE 168.MEDESIS PHARMA SA: KEY STRATERGIES
  • TABLE 169.MITOCHON PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 170.MITOCHON PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 171.MITOCHON PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 172.MITOCHON PHARMACEUTICALS: NET SALES,
  • TABLE 173.MITOCHON PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 174.SUN PHARMACEUTICALS INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 175.SUN PHARMACEUTICALS INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 176.SUN PHARMACEUTICALS INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 177.SUN PHARMACEUTICALS INDUSTRIES LTD.: NET SALES,
  • TABLE 178.SUN PHARMACEUTICALS INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 179.VACCINEX, INC: COMPANY SNAPSHOT
  • TABLE 180.VACCINEX, INC: OPERATING SEGMENTS
  • TABLE 181.VACCINEX, INC: PRODUCT PORTFOLIO
  • TABLE 182.VACCINEX, INC: NET SALES,
  • TABLE 183.VACCINEX, INC: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.HUNTINGTON'S DISEASE TREATMENT MARKET SEGMENTATION
  • FIGURE 2.HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031
  • FIGURE 3.HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.HUNTINGTON'S DISEASE TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.HUNTINGTON'S DISEASE TREATMENT MARKET,BY DRUG TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF APPROVED DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OFFLABEL DRUGS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.HUNTINGTON'S DISEASE TREATMENT MARKET,BY AGE,2021(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF BELOW 50 YEARS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ABOVE 50 YEARS HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.HUNTINGTON'S DISEASE TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACIES HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.HUNTINGTON'S DISEASE TREATMENT MARKET BY REGION,2021
  • FIGURE 23.U.S. HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 24.CANADA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 25.MEXICO HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.GERMANY HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.FRANCE HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.UK HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.ITALY HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.SPAIN HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.REST OF EUROPE HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.JAPAN HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.CHINA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.INDIA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.AUSTRALIA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.SOUTH KOREA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.REST OF ASIA-PACIFIC HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.BRAZIL HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.SAUDI ARABIA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SOUTH AFRICA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.REST OF LAMEA HUNTINGTON'S DISEASE TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 46.COMPETITIVE DASHBOARD
  • FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 48.PRILENIA THERAPEUTICS.: NET SALES ($MILLION)
  • FIGURE 49.SOM BIOTECH.: NET SALES ($MILLION)
  • FIGURE 50.BAUSCH HEALTH COMPANIES INC..: NET SALES ($MILLION)
  • FIGURE 51.TEVA PHARMACEUTICAL INDUSTRIES LTD..: NET SALES ($MILLION)
  • FIGURE 52.NOVARTIS AG.: NET SALES ($MILLION)
  • FIGURE 53.LUPIN.: NET SALES ($MILLION)
  • FIGURE 54.UNIQURE.: NET SALES ($MILLION)
  • FIGURE 55.HIKMA PHARMACEUTICALS PLC.: NET SALES ($MILLION)
  • FIGURE 56.ANNEXON BIOSCIENCES.: NET SALES ($MILLION)
  • FIGURE 57.DR. REDDY'S LABORATORIES LTD..: NET SALES ($MILLION)
  • FIGURE 58.NEUROCRINE BIOSCIENCES.: NET SALES ($MILLION)
  • FIGURE 59.PTC THERAPEUTICS.: NET SALES ($MILLION)
  • FIGURE 60.AOP HEALTH.: NET SALES ($MILLION)
  • FIGURE 61.MEDESIS PHARMA SA.: NET SALES ($MILLION)
  • FIGURE 62.MITOCHON PHARMACEUTICALS.: NET SALES ($MILLION)
  • FIGURE 63.SUN PHARMACEUTICALS INDUSTRIES LTD..: NET SALES ($MILLION)
  • FIGURE 64.VACCINEX, INC.: NET SALES ($MILLION)